SCHEMBL1767931

SCHEMBL1767931

CCCCC(C(=O)OCC)c1ccc2c(c1)C(=O)C(=O)N2

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
TGM2 P21980 5/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
CES1 P23141 4/20 0.38
MAOA P21397 7/20 0.37
MAOB P27338 7/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
CASP3 P42574 2/20 0.35
PDPK1 O15530 1/20 0.35
CAPN9 O14815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768049 0.93 ALDH1A1 (0.43) ALDH1A1TGM2IDO1TDO2CES1
SCHEMBL1768052 0.87 ALDH1A1 (0.40) ALDH1A1TGM2IDO1TDO2CES1
SCHEMBL1767975 0.86 TGM2 (0.42) ALDH1A1TGM2CES1MAOAMAOB
SCHEMBL1768067 0.79 TGM2 (0.47) ALDH1A1TGM2CES1MAOAMAOB
SCHEMBL1767899 0.79 TGM2 (0.44) ALDH1A1TGM2CES1MAOAMAOB
SCHEMBL6204523 0.76 MEN1 (0.49) ALDH1A1CA2
SCHEMBL9114249 0.75 TGM2 (0.45) ALDH1A1TGM2CES1MAOAMAOB
SCHEMBL1767901 0.74 TGM2 (0.50) ALDH1A1TGM2CES1MAOAMAOB
SCHEMBL10410232 0.72 ESR1 (0.46) ALDH1A1CA12CA1CA2CA9
SCHEMBL9113250 0.71 CA12 (0.50) ALDH1A1TGM2IDO1TDO2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-8906930-B2 Quinazoline derivatives MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
EP-2504314-A1 QUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2012-10-03 EP disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
US-20120238582-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-09-20 US disclosed
WO-2011060873-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-05-26 WO disclosed
WO-2011060873-A1 QUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238582-A1 QUINAZOLINE DERIVATIVES HSP90AB1, HSP90AA1, HSP90B1 ALDH1A1 2248/4885TGM2 2166/4885IDO1 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.